Oral Ciprofloxacin Effective for Treatment of Human Plague

Share this content:
Oral Ciprofloxacin Effective for Treatment of Human Plague
Oral Ciprofloxacin Effective for Treatment of Human Plague

WEDNESDAY, Feb. 22, 2017 (HealthDay News) -- Oral ciprofloxacin is effective for the treatment of human plague, caused by Yersinia pestis, according to research published in the March issue of the U.S. Centers for Disease Control and Prevention's Emerging Infectious Diseases.

Titus Apangu, from the Uganda Research Institute in Entebbe, and colleagues examined the efficacy and safety of ciprofloxacin for treatment of plague. Patients with suspected plague seen at six clinics and two hospitals in the West Nile region of Uganda were offered enrollment in a study. Diagnostic samples were collected and oral ciprofloxacin was administered for 10 days. The authors enrolled five patients with culture-confirmed plague who were treated with oral ciprofloxacin: three were admitted and two were treated as outpatients. Four patients had bubonic plague and one had pneumonic plague.

The researchers found that all patients received ciprofloxacin and acetaminophen and two received a bolus of normal saline. Within two days, all patients became afebrile. All had been discharged and had returned to their normal activities at 14 days. No complications were identified.

"Our results add to growing clinical experience and support the broader use of oral ciprofloxacin for treatment of human plague, especially in resource-poor areas where intravenous treatment is limited," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »